Pivikto 200 mg/50 mg Tablet 28's

Pivikto 200 mg/50 mg Tablet belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.

Pivikto 200 mg/50 mg Tablet contains Alpelisib. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

To treat your condition effectually, continue using Pivikto 200 mg/50 mg Tablet for as long as your doctor has prescribed it. The most common side effects include rash, decreased appetite, weight loss, nausea, mouth sores, hair loss, tiredness and weakness, vomiting, changes in certain blood tests, allergic reactions, skin reactions, high blood sugar levels, lung problems, and diarrhea. You should talk to your doctor if you persistently experience these side effects.

Avoid taking Pivikto 200 mg/50 mg Tablet if you are allergic to it. It is not recommended for use in pregnancy. Lactating women do not breastfeed during treatment with Pivikto 200 mg/50 mg Tablet and for one week after the last dose. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.

Pivikto 200 mg/50 mg Tablet contains Alpelisib, which belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

• Rash
• Decreased appetite
• Weight loss
• Nausea
• Mouth sores
• Hair loss
• Tiredness and weakness
• Vomiting
• Changes in certain blood tests
• Severe allergic reactions
• High blood sugar levels
• Lung problems
• Diarrhea

It is not advised during pregnancy, nursing, or for children or young adults under 18. Before taking the Pivikto 200 mg/50 mg Tablet , inform your doctor about all your medical conditions (especially lung infections, diarrhoea, diabetics, kidney or liver impairment), sensitivities or allergic conditions, and all medications you use. Consult your doctor right away if you become pregnant while taking Pivikto 200 mg/50 mg Tablet . Exposure of an unborn child to this medication could cause congenital disabilities, so you should not become pregnant or father a child while on this medication. Effective birth control is required throughout treatment and at least one week after treatment. You should not breastfeed while taking this medication for two weeks after your last dose.

Drug-Drug Interactions: Pivikto 200 mg/50 mg Tablet may interact with anticancer medications (e.g. Apalutamide), anticonvulsant medication (e.g. carbamazepine), anticoagulant medication (e.g. edoxaban), antiepileptic medications (e.g. primidone).

Drug-Food Interactions: Avoid the consumption of alcoholic beverages.

Drug-Disease Interactions: Pivikto 200 mg/50 mg Tablet interacts with disease conditions, including cutaneous manifestations (skin inflammation), diabetes, diarrhoea, osteonecrosis of the jaw (a condition where the jawbone is exposed and not covered by gums), pneumonitis (inflammation in your lung tissues) and renal impairment.

• APALUTAMIDE
• CARBAMAZEPINE
• EDOXABAN
• PRIMIDONE

• After your treatment begins, several dietary adjustments can help you control side effects.
• Anyone suffering from a chronic illness, including cancer, should consume foods high in protein, healthy fats, whole grains, and vitamins and minerals.
• Plant-based proteins are among the greatest meals during chemotherapy or other cancer treatments. They have the highest concentrations of vitamins and minerals, such as nuts, seeds, beans and legumes.
• Eat a healthy diet and exercise regularly to maintain proper weight.
• Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, and herbs.
• De-stress yourself by meditating, reading books, taking a warm bubble bath or listening to soothing music.
• Performing yoga may also help in improving both physical and mental health.
• Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
• Get optimal sleep; rest well.
• Avoid smoking and alcohol consumption.
• Avoid fast food, fried food, processed meats, refined carbs and added sugars.

• Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to Pivikto 200 mg/50 mg Tablet .
• Pregnancy testing is recommended prior to starting treatment with Pivikto 200 mg/50 mg Tablet .
• Do not donate Sperm throughout treatment and at least one week after treatment.

Breast cancer: Breast cancer is a type of cancer that develops in breast cells stimulated by a female sex hormone called estrogen. Breast cancer may form in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and the fatty tissue or the fibrous connective tissue within the breast. The tumour cells invade other healthy breast cells and travel to lymph nodes, a primary pathway for the cancer cells to move to other body parts. Symptoms of breast cancer include a lump in the breast or tissue thickening, which feels different than the normal surrounding tissues, breast pain, redness, swelling, and nipple discharge other than breast milk.

Metastatic breast cancer, also called stage IV breast cancer, has spread to another part of the body, most commonly the bones, lungs, brain, or liver. The process of cancer spreading is called metastasis. Metastasis happens when cancer cells break away from the original tumour in the breast and travel to other parts of the body. These cancer cells travel through the bloodstream or the lymphatic system.